Work

GLP-1 receptor agonists and cardiovascular outcome trials: An update

Year: 2018

Type: review

Abstract: Major cardiovascular (CV) outcome trials with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are currently available. These agonists have proven their CV safety, in harmony with the US Food and Drug Administration (FDA) recommendation for antidiabetic drugs. The potential cardioprotective effect of incretin-based therapies is attributed to their multiple non-glycaemic actions in the CV system, including changes in insulin resistance, weight loss, reduction in blood pressure, improved lipid profile and direct effects on the heart and vascular endothelium. Liraglutide, semaglutide and albiglutide have been demonstrated to reduce the risk of major adverse cardiac events (MACE), whereas lixisenatide and extended-release exenatide had a neutral effect. Thus, it is conceivable that there are different drug-specific properties across the class of GLP-1 RAs. In this review, we discuss the results of the five recently published randomised CV outcome trials with GLP-1 RAs, along with the potential differences and the pleiotropic actions of these agents on the CV system.

Source: Hellenic Journal of Cardiology

DOI: 10.1016/j.hjc.2018.11.008

Authors: Eirini Andrikou, Costas Tsioufis, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios Tousoulis, Nikolaos Papanas

Institutions: National and Kapodistrian University of Athens, Hippocration General Hospital, Democritus University of Thrace, University Hospital of Alexandroupolis

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond